NEW YORK (GenomeWeb News) – Shimadzu and Shimane University in Japan today announced a joint research deal to develop new mass spectrometry-based neonatal screening methods.
Under the terms of the deal, Shimadzu's LCMS-8030 triple quadrupole liquid chromatograph mass spectrometer, a tandem mass spectrometer, will be installed in the laboratory of Seiji Yamaguchi, a professor at Shimane University Faculty of Medicine. The collaborators aim to analyze about 30,000 samples in order to develop new analysis methods and software "to reduce operator workload and to expand the applicability of this method to other dysmetabolic syndrome," Shimadzu said.
The company and Yamaguchi have also developed gas chromatography mass spectrometry software, which makes it possible to perform post-screening investigation.
According to Shimadzu, the Japan Ministry of Health earlier this year noted tandem mass spectrometry in a document distributed to administrative divisions throughout the country as a new examination method for congenital metabolic disorders. Currently about 20 percent of neonatal screening in Japan is tandem mass spec-based, with the technology expected to become widespread nationwide in the future, the company said.
Financial and other terms of the deal were not disclosed.